Crossmark

Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: why screening still matters

Crossref DOI link: https://doi.org/10.1007/s10067-025-07350-x

Published Online: 2025-02-25

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Feuchtenberger, Martin https://orcid.org/0000-0001-8028-8099
Kovacs, Magdolna Szilvia https://orcid.org/0000-0001-9215-6501
Nigg, Axel https://orcid.org/0000-0001-5805-806X
Schäfer, Arne https://orcid.org/0000-0001-6600-3691
Funding

Funding for this research was provided by:

Celltrion Healthcare
License Information

Text and Data Mining valid from 2025-02-25

Version of Record valid from 2025-02-25
More Information

Article History

Received: 16 October 2024

Revised: 14 January 2025

Accepted: 23 January 2025

First Online: 25 February 2025

Declarations

:

: AS reports personal fees from Amgen, AstraZeneca, Novo Nordisk Pharma GmbH, outside the submitted work. MF reports personal fees from AbbVie, personal fees from Roche, and personal fees from UCB outside of the submitted work. MSK and AN declare no disclosures relevant to this manuscript.

Document is current

Any future updates will be listed below